Short-term upregulation of central VEGF may exert antidepressant effects by promoting the benign remodeling of neurovascular networks, and its subsequent return to baseline levels during treatment can avoid BBB damage, providing novel insights for the management of rapid-onset and treatment-resistant depression. This evidence concerns the gene VEGFA and major depressive disorder.